$CPRX
CATALYST PHARMACEUTICALS, INC.

2019 Q4 Form 10-K Financial Statement

#000119312520075048 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $30.12M $30.90M $28.84M
YoY Change 5924.51%
Cost Of Revenue $4.400M $4.387M $4.262M
YoY Change
Gross Profit $25.72M $26.51M $24.58M
YoY Change
Gross Profit Margin 85.38% 85.8% 85.22%
Selling, General & Admin $11.41M $8.068M $8.988M
YoY Change 64.65% 121.39% 241.6%
% of Gross Profit 44.36% 30.43% 36.57%
Research & Development $6.310M $4.597M $4.629M
YoY Change -25.06% 1.29% 24.96%
% of Gross Profit 24.53% 17.34% 18.84%
Depreciation & Amortization $20.00K $6.532K $10.00K
YoY Change 100.0% -29.72% 22.31%
% of Gross Profit 0.08% 0.02% 0.04%
Operating Expenses $17.72M $12.66M $17.88M
YoY Change 15.51% 54.78% 182.18%
Operating Profit $8.007M $13.85M $10.96M
YoY Change -153.94% -269.2% -272.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $400.0K $393.4K $450.4K
YoY Change 17.65% 14.45% 21.5%
Pretax Income $8.410M $14.24M $11.41M
YoY Change -158.0% -281.64% -291.27%
Income Tax $480.0K $608.4K $449.7K
% Of Pretax Income 5.71% 4.27% 3.94%
Net Earnings $7.930M $13.63M $10.96M
YoY Change -154.69% -273.88% -283.73%
Net Earnings / Revenue 26.32% 44.11% 38.01%
Basic Earnings Per Share $0.08 $0.13 $0.11
Diluted Earnings Per Share $0.07 $0.13 $0.10
COMMON SHARES
Basic Shares Outstanding 103.0M 103.0M 102.9M
Diluted Shares Outstanding 107.0M 105.9M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.50M $76.50M $59.90M
YoY Change 76.64% 23.99% -12.43%
Cash & Equivalents $89.51M $44.98M $23.42M
Short-Term Investments $5.000M $31.60M $36.50M
Other Short-Term Assets $4.300M $3.300M $1.500M
YoY Change 152.94% 312.5% 114.29%
Inventory $1.957M $599.8K $269.9K
Prepaid Expenses
Receivables $10.54M $10.10M $10.38M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $111.4M $90.58M $72.06M
YoY Change 101.79% 44.97% 4.3%
LONG-TERM ASSETS
Property, Plant & Equipment $210.5K $141.1K $147.6K
YoY Change -14.24% -29.84% -21.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $5.000M $5.000M
YoY Change -100.0% 0.0% 0.0%
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $1.013M $6.111M $6.178M
YoY Change -80.76% 16.87% 18.79%
TOTAL ASSETS
Total Short-Term Assets $111.4M $90.58M $72.06M
Total Long-Term Assets $1.013M $6.111M $6.178M
Total Assets $112.4M $96.69M $78.23M
YoY Change 85.9% 42.8% 5.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.117M $4.147M $3.329M
YoY Change 76.16% 209.25% 260.8%
Accrued Expenses $19.98M $13.84M $10.82M
YoY Change 178.52% 550.32% 401.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.10M $17.98M $14.15M
YoY Change 153.37% 418.46% 359.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change 200.0% 250.0% 700.0%
Total Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change 200.0% 250.0% 700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.10M $17.98M $14.15M
Total Long-Term Liabilities $600.0K $700.0K $800.0K
Total Liabilities $24.75M $18.71M $14.95M
YoY Change 156.01% 414.92% 363.6%
SHAREHOLDERS EQUITY
Retained Earnings -$128.7M -$136.6M -$150.2M
YoY Change -19.85% -6.47% 8.7%
Common Stock $103.4K $103.0K $102.9K
YoY Change 0.64% 0.34% 0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.63M $77.98M $63.28M
YoY Change
Total Liabilities & Shareholders Equity $112.4M $96.69M $78.23M
YoY Change 85.9% 42.8% 5.31%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $7.930M $13.63M $10.96M
YoY Change -154.69% -273.88% -283.73%
Depreciation, Depletion And Amortization $20.00K $6.532K $10.00K
YoY Change 100.0% -29.72% 22.31%
Cash From Operating Activities $12.29M $16.26M $14.02M
YoY Change -255.57% -333.62% -394.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $31.65M $5.050M -$9.860M
YoY Change 130.01% -33.55% 99.6%
Cash From Investing Activities $31.65M $5.050M -$9.880M
YoY Change 131.02% -33.29% 99.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 580.0K 260.0K 190.0K
YoY Change 286.67% 160.0% 1800.0%
NET CHANGE
Cash From Operating Activities 12.29M 16.26M 14.02M
Cash From Investing Activities 31.65M 5.050M -9.880M
Cash From Financing Activities 580.0K 260.0K 190.0K
Net Change In Cash 44.52M 21.57M 4.330M
YoY Change 648.24% 2938.03% -144.64%
FREE CASH FLOW
Cash From Operating Activities $12.29M $16.26M $14.02M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow $12.29M $16.26M $14.03M
YoY Change -256.56% -334.63% -395.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Trading Symbol
TradingSymbol
CPRX
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICALS, INC.
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103408699
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001369568
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
36922213
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10536997
CY2019Q4 us-gaap Inventory Net
InventoryNet
1956792
CY2018Q4 us-gaap Inventory Net
InventoryNet
56012
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4351074
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1649781
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89511710
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16559400
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
5007050
CY2019Q4 us-gaap Assets Current
AssetsCurrent
111363623
CY2018Q4 us-gaap Assets Current
AssetsCurrent
55187406
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
5008243
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
210467
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
245425
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2019Q4 us-gaap Assets
Assets
112376230
CY2018Q4 us-gaap Assets
Assets
60449962
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4117447
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2337367
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24098742
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9511354
CY2019Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2018Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
154799
CY2019Q4 us-gaap Liabilities
Liabilities
24746274
CY2018Q4 us-gaap Liabilities
Liabilities
9666153
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
103397
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
102739
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
216205678
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
211265279
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128688624
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160563961
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9505
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20248
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
87629956
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
50783809
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
112376230
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60449962
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
103397033
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102739257
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
103397033
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102739257
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14759139
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18842752
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19919204
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36881187
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15875961
CY2019 cprx Total Operating Expenses
TotalOperatingExpenses
70483078
CY2018 cprx Total Operating Expenses
TotalOperatingExpenses
35795165
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
31823259
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-35295165
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1585774
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1291651
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33409033
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34003514
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29753
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20248
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31905090
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34023762
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1533696
CY2019 us-gaap Profit Loss
ProfitLoss
31875337
CY2018 us-gaap Profit Loss
ProfitLoss
-34003514
CY2019 us-gaap Depreciation
Depreciation
54327
CY2018 us-gaap Depreciation
Depreciation
37978
CY2019 cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
243399
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3824815
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3550644
CY2019 cprx Change In Accrued Interest And Accretion Of Discount On Investments
ChangeInAccruedInterestAndAccretionOfDiscountOnInvestments
290805
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10536997
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1900780
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
56012
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2701293
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
476037
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1780080
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
391792
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12540197
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4850743
CY2019 cprx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
276807
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34611473
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26147545
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19369
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92018
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34725401
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36790854
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
71969365
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
21800000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37224595
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15082872
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4448
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1116242
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
297563
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1116242
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
293115
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
72952310
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-40937302
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57496702
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;">b.</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">USE OF ESTIMATES. </div>The preparation of financial statements in conformity with<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>accounting </div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">principles</div><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"> generally accepted in the U.S<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
13845152
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
8006687
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-644503
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
10959948
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
13630179
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
7929713
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102944316
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102633884
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3076620
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106020936
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102633884
CY2019 us-gaap Trading Securities Realized Gain Loss
TradingSecuritiesRealizedGainLoss
80045
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4600000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10500000
CY2018 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.79
CY2018 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.64
CY2019 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.79
CY2019 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.20
CY2019 cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
three months
CY2018 cprx Trading Securities Sales
TradingSecuritiesSales
0
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-11-30
CY2019 cprx Minimum Amortization Period Of Compensation Cost On Straight Line Basis
MinimumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P1Y
CY2019 cprx Maximum Amortization Period Of Compensation Cost On Straight Line Basis
MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P5Y
CY2019Q4 cprx Number Of Trading Securities
NumberOfTradingSecurities
0
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
64939250
CY2019 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
9505
CY2019 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
64929745
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15389107
CY2018 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
20248
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15409355
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66436
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19981295
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7173987
CY2019Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
0
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30897444
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30122555
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-987769
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
10959189
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
296316
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
329725
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21220
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
793252
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300518
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
647532
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
948050
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
339605
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
349788
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
329662
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1019055
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
71005
CY2019Q4 cprx Lessee Operating Lease Liability Payments Total
LesseeOperatingLeaseLiabilityPaymentsTotal
948050
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
242155
CY2019Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
1183513
CY2018Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
821633
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1241526
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1311061
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3064645
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1941449
CY2019Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
8751991
CY2018Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
3000000
CY2019Q4 cprx Accrued Variable Consideration
AccruedVariableConsideration
884764
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
33408
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1533696
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
172332
CY2018Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
154799
CY2019Q4 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
647532
CY2018Q4 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
154799
CY2019Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
20628827
CY2018Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
7328786
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12448438
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28837900
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2018Q4 us-gaap Revenues
Revenues
500000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5933440
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6335855
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8182603
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14843267
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5699892
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5965140
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7838873
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-14499609
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
268000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
123000
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2019Q4 cprx Number Of Votes Entitlement For Each Share Held By Common Stock Holders
NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders
1
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.259
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019 cprx Effective Income Tax Credits Rate
EffectiveIncomeTaxCreditsRate
-0.025
CY2018 cprx Effective Income Tax Credits Rate
EffectiveIncomeTaxCreditsRate
0.014
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.005
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.046
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10645128
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19867591
CY2019Q4 cprx Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
12894926
CY2018Q4 cprx Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
13861147
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14320860
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
12625275
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
3183767
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1919434
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
355023
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
109779
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41628754
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48383226
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41628754
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48383226
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6800000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
41500000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
79000000
CY2019 cprx Percentage Of Limited Utilization Of Taxable Income Per Year
PercentageOfLimitedUtilizationOfTaxableIncomePerYear
0.80
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
1 year
CY2019 us-gaap Lessor Operating Lease Option To Terminate
LessorOperatingLeaseOptionToTerminate
1 year
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2019Q2 dei Entity Public Float
EntityPublicFloat
367949157
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.69
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.93
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3864995
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2193294
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1899862
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
274864
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
11478334
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y10M20D
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.95
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5844819
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P3Y10M13D
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.41
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.755
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.82
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 cprx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
CY2018 cprx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0151
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0253
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0209
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0288
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10532500
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.54
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2183500
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.54
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
660998
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.72
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
511668
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.73
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
65000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.90
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11478334
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.95
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5844819
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.41
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M13D
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102306337
CY2018 us-gaap Revenues
Revenues
500000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11590899
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8084671
CY2019 cprx Operating Losses Carryforwards Expiration Dates
OperatingLossesCarryforwardsExpirationDates
Beginning in 2024 and ending in 2037
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2018 cprx Change In Accrued Interest And Accretion Of Discount On Investments
ChangeInAccruedInterestAndAccretionOfDiscountOnInvestments
443139
CY2019Q4 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1526013
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1263129
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
800261
CY2019Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
501251
CY2018Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
170552
CY2019Q4 cprx Prepaid Research Fee
PrepaidResearchFee
481057
CY2018Q4 cprx Prepaid Research Fee
PrepaidResearchFee
358209
CY2019Q4 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
62959
CY2018Q4 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
17030
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
516665
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
303729
CY2019 cprx Period Of Collaboration Agreement
PeriodOfCollaborationAgreement
P10Y
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1533696
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0481
CY2019Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
229050
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
80963812
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10549
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3535647
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
297563
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-20248
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-34003514
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3780086
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1116242
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
44729
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
29753
CY2019 us-gaap Net Income Loss
NetIncomeLoss
31875337
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M20D
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
29753
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-20248
CY2019Q4 cprx Accrued Purchases Current
AccruedPurchasesCurrent
1313310
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
1535000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">o.</div></div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONCENTRATION OF RISK.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e., money market funds), investments and accounts receivable, net. The Company places its cash <div style="display:inline;">and cash </div>equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sells its product in the United States through an exclusive distributor (its Customer) to specialty pharmacies. Therefore, its distributor and specialty pharmacies account for all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions.</div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, Firdapse<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>, and expects Firdapse<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> to constitute virtually all of product revenue for the foreseeable future. The Company&#8217;s success depends on its ability to effectively commercialize Firdapse<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company relies exclusively on third parties to formulate and manufacture Firdapse</div><div style="font-size: 7.4pt; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and its drug candidates. The commercialization of Firdapse</div><div style="font-size: 7.4pt; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of Firdapse</div><div style="font-size: 7.4pt; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of its drugs. </div></div></div>
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;">u.</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RECLASSIFICATIONS.</div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="font-size: 10pt;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organization and Description of Business. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the &#8220;Company&#8221;) is a biopharmaceutical company focused on developing and commercializing innovati<div style="display:inline;">ve</div> therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Anti-MuSK antibody positive myasthenia gravis (MuSK-MG), and Spinal Muscular Atrophy (SMA) Type 3. The Company (f/k/a Catalyst Pharmaceutical Partners, Inc.) was incorporated in Delaware in July 2006. It is the successor by merger to Catalyst Pharmaceutical Partners, Inc., a Florida corporation, which commenced operations in January 2002. </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;28, 2018, the U.S. Food and Drug Administration, or FDA, granted approval of Firdapse<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> for the treatment of adults with LEMS (ages 17 and above). On January&#160;15, 2019, the Company launched its first product, Firdapse<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>, in the United States for the treatment of adults with LEMS. </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its product. The Company incurred operating losses in each period from inception, and started reporting operating income during the year ended December 31, 2019. The Company has been able to fund its cash needs to date through several public and private offerings of its securities and from revenues from its product sales. See Note 11 (Stockholders&#8217; Equity). </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Capital Resources </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">While there can be no assurance, based on currently available information, the Company estimates that it currently has sufficient resources to support its operations for at least the next 12 months from the issuance date of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may raise required funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#8217;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company&#8217;s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company&#8217;s business.&#160;</div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 cprx Tax Credit Losses Carryforwards Expiration Dates
TaxCreditLossesCarryforwardsExpirationDates
beginning in 2032 and ending in 2040

Files In Submission

Name View Source Status
0001193125-20-075048-index-headers.html Edgar Link pending
0001193125-20-075048-index.html Edgar Link pending
0001193125-20-075048.txt Edgar Link pending
0001193125-20-075048-xbrl.zip Edgar Link pending
cprx-20191231.xml Edgar Link completed
cprx-20191231.xsd Edgar Link pending
cprx-20191231_cal.xml Edgar Link unprocessable
cprx-20191231_def.xml Edgar Link unprocessable
cprx-20191231_lab.xml Edgar Link unprocessable
cprx-20191231_pre.xml Edgar Link unprocessable
d838851d10k.htm Edgar Link pending
d838851dex211.htm Edgar Link pending
d838851dex231.htm Edgar Link pending
d838851dex311.htm Edgar Link pending
d838851dex312.htm Edgar Link pending
d838851dex321.htm Edgar Link pending
d838851dex322.htm Edgar Link pending
d838851dex45.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending